Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

This study has been completed.
Information provided by:
SymBio Pharmaceuticals Identifier:
First received: November 18, 2008
Last updated: May 27, 2010
Last verified: May 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2010
  Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)